Brainsway LTD

Brainsway Ltd. Chief Scientist Yiftach Roth reported transactions involving the sale of ordinary shares.

Brainsway Ltd. director Ety Mitrany reported transactions involving the sale of ordinary shares.

Brainsway Ltd. director Rayten Michal Mitrany reported transactions involving the acquisition and disposition of ordinary shares and stock options.

Valor BrainsWay Holdings, LLC exercised a warrant for 553,730 American Depository Shares of Brainsway Ltd., increasing its beneficial ownership to 13.7% of the company.

BrainsWay Ltd. and Valor BrainsWay Holdings, LLC have amended their warrant agreement, removing the cashless exercise mechanism for warrants to purchase up to 1,500,000 American Depositary Shares.

Harel Insurance Investments & Financial Services Ltd. has amended its Schedule 13G filing to report beneficial ownership of 3,265,397 ordinary shares in Brainsway Ltd., representing 8.3% of the class.

Meitav Investment House Ltd. and its subsidiaries have reported beneficial ownership of 6.31% of Brainsway Ltd.'s ordinary shares.

Masters Capital Management, LLC and Michael Masters have filed an amendment to Schedule 13G, reporting beneficial ownership of 3.8% of BrainsWay Ltd. ordinary shares as of March 31, 2026.

Harel Insurance Investments & Financial Services Ltd. has increased its beneficial ownership of Brainsway Ltd. American Depositary Shares to 6.8%, holding 2,677,117 shares as of March 31, 2026.

Meitav Investment House Ltd. has filed a Schedule 13G reporting a 5.24% beneficial ownership stake in Brainsway Ltd. as of March 31, 2026.

Harel Insurance Investments & Financial Services Ltd. has reported a 5.2% beneficial ownership stake in Brainsway Ltd. through a Schedule 13G filing.